XLR-11

XLR-11 is a drug that was initially developed in the mid-20th century. It is a synthetic cannabinoid and was the first of its kind to be identified as an ingredient in synthetic cannabis blends in Japan in 2012. The drug is named after the XLR rocket engine that was developed by the U.S. Rocketdyne company to power the X-1 rocket plane.

History

XLR-11 was first synthesized in the mid-20th century by a team of chemists at the pharmaceutical company Pfizer. However, it was not until 2012 that it was identified as an ingredient in synthetic cannabis blends in Japan. This marked the first time that XLR-11 had been detected in a consumer product.

Pharmacology

XLR-11 is a full agonist of the CB1 receptor, which is primarily found in the brain. This receptor is part of the endocannabinoid system, which plays a role in a variety of physiological processes including appetite, pain-sensation, mood, and memory. XLR-11 is also a full agonist of the CB2 receptor, which is primarily found in the immune system.

Legal status

In the United States, XLR-11 is a Schedule I controlled substance, which means it has a high potential for abuse and no accepted medical use. It is also illegal in several other countries, including the United Kingdom and New Zealand.

Health effects

The health effects of XLR-11 are not well-studied. However, it is known that synthetic cannabinoids can cause a variety of adverse effects, including seizures, psychosis, and death. In addition, because XLR-11 is often found in synthetic cannabis blends, users may be exposed to a variety of other dangerous substances.

See also

• Synthetic cannabinoids
• Cannabinoid receptor
• Endocannabinoid system

XLR-11 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia